FAS and RAS related Apoptosis defects: From autoimmunity to leukemia

The human adaptive immune system recognizes almost all the pathogens that we encounter and all the tumor antigens that may arise during our lifetime. Primary immunodeficiencies affecting lymphocyte development or function therefore lead to severe infections and tumor susceptibility. Furthermore, the fact that autoimmunity is a frequent feature of primary immunodeficiencies reveals a third function of the adaptive immune system: its self‐regulation. Indeed, the generation of a broad repertoire of antigen receptors (via a unique strategy of random somatic rearrangements of gene segments in T cell and B cell receptor loci) inevitably creates receptors with specificity for self‐antigens and thus leads to the presence of autoreactive lymphocytes. There are many different mechanisms for controlling the emergence or action of autoreactive lymphocytes, including clonal deletion in the primary lymphoid organs, receptor editing, anergy, suppression of effector lymphocytes by regulatory lymphocytes, and programmed cell death. Here, we review the genetic defects affecting lymphocyte apoptosis and that are associated with lymphoproliferation and autoimmunity, together with the role of somatic mutations and their potential involvement in more common autoimmune diseases.

[1]  F. Locatelli,et al.  Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia , 2018, Expert review of hematology.

[2]  D. Faustman,et al.  Structural principles of tumor necrosis factor superfamily signaling , 2018, Science Signaling.

[3]  M. Loh,et al.  Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia , 2017, Nature Communications.

[4]  F. Rieux-Laucat,et al.  Lymphadenopathy driven by TCR-Vγ8Vδ1 T-cell expansion in FAS-related autoimmune lymphoproliferative syndrome. , 2017, Blood advances.

[5]  C. Sticht,et al.  Caspase-10 Negatively Regulates Caspase-8-Mediated Cell Death, Switching the Response to CD95L in Favor of NF-κB Activation and Cell Survival , 2017, Cell reports.

[6]  M. Raffeld,et al.  Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. , 2017, Blood.

[7]  M. Seear,et al.  The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. , 2017, Clinical immunology.

[8]  Matthew S. Lebo,et al.  Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome , 2017, European Journal of Human Genetics.

[9]  K. Chakrabandhu,et al.  Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and Diseases , 2016, Front. Immunol..

[10]  K. Koike,et al.  Diagnosis and treatment of juvenile myelomonocytic leukemia , 2016, Pediatrics international : official journal of the Japan Pediatric Society.

[11]  J. Ritz,et al.  CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice , 2016, Immunity.

[12]  C. Croce,et al.  MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment , 2016, Oncotarget.

[13]  K. Schwarz,et al.  Disturbed B-lymphocyte selection in autoimmune lymphoproliferative syndrome. , 2016, Blood.

[14]  A. Baruchel,et al.  Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network , 2015, Nature Genetics.

[15]  J. B. Oliveira,et al.  JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. , 2015, Blood.

[16]  S. Miyano,et al.  Somatic Mosaicism for a NRAS Mutation Associates with Disparate Clinical Features in RAS-associated Leukoproliferative Disease: a Report of Two Cases , 2015, Journal of Clinical Immunology.

[17]  J. B. Oliveira,et al.  Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings , 2015, Journal of Clinical Immunology.

[18]  M. Greene,et al.  Cancer spectrum and frequency among children with Noonan, Costello, and cardio-facio-cutaneous syndromes , 2015, British Journal of Cancer.

[19]  C. Dvorak,et al.  Juvenile myelomonocytic leukemia. , 2015, Pediatric clinics of North America.

[20]  A. Borkhardt,et al.  A novel homozygous Fas ligand mutation leads to early protein truncation, abrogation of death receptor and reverse signaling and a severe form of the autoimmune lymphoproliferative syndrome. , 2014, Clinical immunology.

[21]  C. Niemeyer RAS diseases in children , 2014, Haematologica.

[22]  T. Molina,et al.  Defective anti-polysaccharide response and splenic marginal zone disorganization in ALPS patients. , 2014, Blood.

[23]  K. Schwarz,et al.  Abnormally differentiated CD4+ or CD8+ T cells with phenotypic and genetic features of double negative T cells in human Fas deficiency. , 2014, Blood.

[24]  T. Tarrant,et al.  Autoimmune Lymphoproliferative Syndrome: an Update and Review of the Literature , 2014, Current Allergy and Asthma Reports.

[25]  F. Rieux-Laucat,et al.  RAS-associated lymphoproliferative disease evolves into severe juvenile myelo-monocytic leukemia. , 2014, Blood.

[26]  S. Miyano,et al.  Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia , 2013, Nature Genetics.

[27]  M. Loh,et al.  Deficiency of CREB and over expression of miR-183 in juvenile myelomonocytic leukemia , 2013, Leukemia.

[28]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. , 2013, The Journal of allergy and clinical immunology.

[29]  P. Krammer,et al.  The chains of death , 2013, Cell cycle.

[30]  C. Kim,et al.  Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies , 2012, American journal of medical genetics. Part A.

[31]  M. McDermott,et al.  Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases , 2012, Current opinion in rheumatology.

[32]  P. Krammer,et al.  Regulation of CD95/Fas signaling at the DISC , 2011, Cell Death and Differentiation.

[33]  D. Steinemann,et al.  Constitutional trisomy 8p11.21‐q11.21 mosaicism: a germline alteration predisposing to myeloid leukaemia , 2011, British journal of haematology.

[34]  J. B. Oliveira,et al.  Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. , 2011, Blood.

[35]  T. Morio,et al.  Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. , 2011, Blood.

[36]  H. Fuchs,et al.  Immune modulation by Fas ligand reverse signaling: lymphocyte proliferation is attenuated by the intracellular Fas ligand domain. , 2011, Blood.

[37]  F. Rieux-Laucat,et al.  Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation. , 2011, The Journal of clinical investigation.

[38]  F. Rieux-Laucat,et al.  Whole-exome-sequencing-based discovery of human FADD deficiency. , 2010, American journal of human genetics.

[39]  F. Rieux-Laucat,et al.  Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. , 2010, Blood.

[40]  J. B. Oliveira,et al.  Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. , 2010, Blood.

[41]  M. V. D. van den Heuvel-Eibrink,et al.  Molecular basis of juvenile myelomonocytic leukemia , 2010, Haematologica.

[42]  H. Hasle Malignant Diseases in Noonan Syndrome and Related Disorders , 2009, Hormone Research in Paediatrics.

[43]  F. Rieux-Laucat,et al.  FAS-L, IL-10, and double-negative CD4- CD8- TCR alpha/beta+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function. , 2009, Blood.

[44]  M. Loh,et al.  Juvenile myelomonocytic leukemia: a report from the 2nd International JMML Symposium. , 2009, Leukemia research.

[45]  F. Rieux-Laucat,et al.  Human TCR α/β+ CD4−CD8− Double-Negative T Cells in Patients with Autoimmune Lymphoproliferative Syndrome Express Restricted Vβ TCR Diversity and Are Clonally Related to CD8+ T Cells1 , 2008, The Journal of Immunology.

[46]  M. Willingham,et al.  Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. , 2008, Immunity.

[47]  A. Strasser,et al.  Apoptosis Regulators Fas and Bim Cooperate in Shutdown of Chronic Immune Responses and Prevention of Autoimmunity , 2008, Immunity.

[48]  L. Davis,et al.  Combined deficiency of proapoptotic regulators Bim and Fas results in the early onset of systemic autoimmunity. , 2008, Immunity.

[49]  M. Ferretti,et al.  Co-inherited mutations of Fas and caspase-10 in development of the autoimmune lymphoproliferative syndrome , 2007, BMC Immunology.

[50]  J. Puck,et al.  Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib , 2007, BMC Medical Genetics.

[51]  Inna N. Lavrik,et al.  Life and death in peripheral T cells , 2007, Nature Reviews Immunology.

[52]  K. Koike,et al.  Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. , 2007, Blood.

[53]  Peter J. Munson,et al.  NRAS mutation causes a human autoimmune lymphoproliferative syndrome , 2007, Proceedings of the National Academy of Sciences.

[54]  A. Anel,et al.  A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome. , 2006, Blood.

[55]  A. Schäffer,et al.  Genetic alterations in caspase-10 may be causative or protective in autoimmune lymphoproliferative syndrome , 2006, Human Genetics.

[56]  L. Salmena,et al.  Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder , 2005, The Journal of experimental medicine.

[57]  Lucio Luzzatto,et al.  A quantitative measurement of the human somatic mutation rate. , 2005, Cancer research.

[58]  F. Rieux-Laucat,et al.  Autoimmune lymphoproliferative syndrome with somatic Fas mutations. , 2004, The New England journal of medicine.

[59]  C. Babinet,et al.  Complete Loss of Fas Ligand Gene Causes Massive Lymphoproliferation and Early Death, Indicating a Residual Activity of gld Allele 1 , 2004, The Journal of Immunology.

[60]  J. Puck,et al.  Immune disorders caused by defects in the caspase cascade , 2003, Current allergy and asthma reports.

[61]  Peter Guttorp,et al.  Evidence that the number of hematopoietic stem cells per animal is conserved in mammals. , 2002, Blood.

[62]  F. Rieux-Laucat,et al.  Inactivation of the Fas gene by Alu insertion: retrotransposition in an intron causing splicing variation and autoimmune lymphoproliferative syndrome , 2002, Genes and Immunity.

[63]  J. Puck,et al.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency , 2002, Nature.

[64]  C. Mohan,et al.  Genetic Dissection of SLE , 2002, The Journal of experimental medicine.

[65]  F. Rieux-Laucat,et al.  Differential sensitivity of Jurkat and primary T cells to caspase‐independent cell death triggered upon Fas stimulation , 2002, European journal of immunology.

[66]  Brian Seed,et al.  Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule , 2000, Nature Immunology.

[67]  F. Martinon,et al.  The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways , 2000, Current Biology.

[68]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[69]  E. Mantadakis,et al.  Prevalence of priapism in children and adolescents with sickle cell anemia. , 1999, Journal of pediatric hematology/oncology.

[70]  J. Puck,et al.  Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II , 1999, Cell.

[71]  N. Kabra,et al.  Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1 , 1998, Nature.

[72]  D. Kono,et al.  Loci predisposing to autoimmunity in MRL-Fas lpr and C57BL/6-Faslpr mice. , 1998, The Journal of clinical investigation.

[73]  T. Miyawaki,et al.  Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder. , 1998, International immunology.

[74]  Pamela J. Fink,et al.  Maximal Proliferation of Cytotoxic T Lymphocytes Requires Reverse Signaling through Fas Ligand , 1998, The Journal of experimental medicine.

[75]  B. Bader-Meunier,et al.  Occurrence of myeloproliferative disorder in patients with Noonan syndrome. , 1997, The Journal of pediatrics.

[76]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) , 1997, Blood.

[77]  J. Harbott,et al.  Chronic myelomonocytic leukemia in childhood. A retrospective analysis of 110 cases. , 1997 .

[78]  L. Notarangelo,et al.  Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. , 1997, Blood.

[79]  F. Rieux-Laucat,et al.  Clinical, immunological, and pathological consequences of Fas-deficient conditions , 1996, The Lancet.

[80]  P. Schur,et al.  Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. , 1996, The Journal of clinical investigation.

[81]  N. Yoshida,et al.  Enhanced and accelerated lymphoproliferation in Fas-null mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[82]  D. Bellgrau,et al.  A role for CD95 ligand in preventing graft rejection , 1995, Nature.

[83]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[84]  F. Rieux-Laucat,et al.  Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. , 1995, Science.

[85]  E. Lacy,et al.  Massive upregulation of the Fas ligand in lpr and gld mice: implications for Fas regulation and the graft-versus-host disease-like wasting syndrome , 1995, The Journal of experimental medicine.

[86]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[87]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[88]  H. Ikeda,et al.  A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse , 1990, The Journal of experimental medicine.

[89]  P. Möller,et al.  Monoclonal antibody-mediated tumor regression by induction of apoptosis. , 1989, Science.

[90]  S. Yonehara,et al.  A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor , 1989, The Journal of experimental medicine.

[91]  F. Takei Unique surface phenotype of T cells in lymphoproliferative autoimmune MRL/Mp-lpr/lpr mice. , 1984, Journal of Immunology.

[92]  A. Theofilopoulos,et al.  Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains , 1978, The Journal of experimental medicine.

[93]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[94]  R. Lockshin,et al.  PROGRAMMED CELL DEATH--I. CYTOLOGY OF DEGENERATION IN THE INTERSEGMENTAL MUSCLES OF THE PERNYI SILKMOTH. , 1965, Journal of insect physiology.

[95]  L. Notarangelo,et al.  Autoimmune lymphoproliferative syndrome caused by a homozygous FasL mutation that disrupts FasL assembly. , 2016, The Journal of allergy and clinical immunology.

[96]  E. Paz-Artal,et al.  Autoimmune lymphoproliferative syndrome due to somatic FAS mutation (ALPS-sFAS) combined with a germline caspase-10 (CASP10) variation. , 2016, Immunobiology.

[97]  Jb Oliveira,et al.  NRAS mutation causes a human autoimmune lymphopro-liferative disease , 2007 .

[98]  A. Chiocchetti,et al.  The broad spectrum of autoimmune lymphoproliferative disease: molecular bases, clinical features and long-term follow-up in 31 patients. , 2006, Haematologica.

[99]  A. Langerak,et al.  Autoimmune Lymphoproliferative Syndrome (ALPS) in a Child from Consanguineous Parents: A Dominant or Recessive Disease? , 2000, Pediatric Research.

[100]  D. Chitayat,et al.  Juvenile myelomonocytic leukemia and Noonan syndrome. , 1999, Journal of pediatric hematology/oncology.

[101]  S. Nagata,et al.  Fas and Fas ligand: lpr and gld mutations. , 1995, Immunology today.